This is unpublished


he, him, his
Physician & Research Faculty
Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology, University of Washington
Medical Director, Adult Blood and Marrow Transplant Program, Seattle Cancer Care Alliance and Fred Hutch
Sites of Practice
Seattle Cancer Care Alliance
UW Medical Center - Montlake

Photo: SCCA

Education, Training, Board Certifications 

  • M.D., Freie Universität Berlin, Germany
  • Ph.D., Freie Universität Berlin, Germany
  • Residency in Internal Medicine, UW
  • Fellowship in Oncology, UW
  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Clinical Expertise  

  • Hematopoietic stem cell transplantation
  • Graft-vs.-host disease




Research and/or clinical interests 

Dr. Marco Mielcarek’s research focuses on graft-vs.-host disease, or GVHD, a potentially life-threatening complication in which newly transplanted donor cells attack the patient’s body. Dr. Mielcarek and his research colleagues are testing in clinical trials how to prevent GVHD better and how to treat it effectively without causing unwanted toxicity. He and his colleagues have shown that carefully timed infusions of high doses of cyclophosphamide, a common chemotherapy drug, can safely and effectively prevent GVHD after growth factor-mobilized blood stem cell transplantation. As Medical Director of the Adult Blood and Marrow Transplant Program at Seattle Cancer Care Alliance and Fred Hutch, Dr. Mielcarek's focus is on constantly improving the high level of clinical care in the program, and on seamlessly integrating cutting-edge clinical research with the patients' care experience.